Values as of: 2025-01-08
COMMON STOCK | Medical Devices |
Last Closing
USD 0.035Change
-0.01 (-12.50)%Market Cap
USD 0.01BVolume
1.16MAnalyst Target
N/AVerdict
Verdict
Therma Bright Inc. acquires, develops, manufactures, and markets proprietary healthcare and medical devices focused on respiratory diseases, vascular health, and consumer medical devices for consumer and institutional marketplace. The company's products include AcuVid, an antigen and antibody rapid screening test for COVID-19; InterceptCS, a cold sore prevention system, which provides controlled topical heat without the risk of burning the skin; Benepod, a hot and cold contrast therapy device for pain relief without pain relieving medication; Venowave, a medical compression pump designed to treat and alleviate the symptoms associated with poor circulation; and TherOZap, a thermal therapy insect device that reduces the inflammatory response, as well as relieves the symptoms of pain, itching, and inflammation associated with insect bites and stings. It also offers Inretio, a medical device for ischemic stroke treatment; Digital Cough Test (DCT), an app that uses artificial intelligence to detect multiple respiratory diseases; and inhaled statin therapy for the treatment of COVID-19 pneumonia and acute respiratory distress syndrome in hospitalized patients. The company serves consumers and medical professionals. The company was formerly known as The Jenex Corporation and changed its name to Therma Bright Inc. in February 2018. Therma Bright Inc. was incorporated in 2001 and is based in Toronto, Canada.
Company Website : https://www.thermabright.com
Currency: CAD
Country : Canada
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| TLT:CA | Theralase Technologies Inc. |
-0.01 (-1.64%) |
USD 0.07B |
| PINK:CA | Perimeter Medical Imaging AI I.. |
+0.03 (+6.02%) |
USD 0.05B |
| ASG:CA | Aurora Spine Corp |
+0.01 (+2.13%) |
USD 0.03B |
| MDX:CA | MedX Health Corp |
N/A |
USD 0.02B |
| NGMD:CA | NuGen Medical Devices Inc |
N/A |
USD 0.02B |
| VPT:CA | VentriPoint Diagnostics Ltd |
+0.01 (+4.76%) |
USD 0.02B |
| EVMT:CA | Evome Medical Technologies Inc.. |
+0.01 (+3.45%) |
USD 0.01B |
| FREQ:CA | Frequency Exchange Corp. |
N/A |
USD 0.01B |
| CNVI:CA | Conavi Medical Corp. |
-0.05 (-7.35%) |
N/A |
N/A
| Market Performance vs. Industry/Classification (Medical Devices) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Trailing 12 Months | |||||||
| Capital Gain | 40.00% | 88% | B+ | 78% | C+ | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 40.00% | 88% | B+ | 78% | C+ | ||
| Trailing 5 Years | |||||||
| Capital Gain | 133.33% | 100% | F | 88% | B+ | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 133.33% | 100% | F | 88% | B+ | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 411.17% | 100% | F | 98% | N/A | ||
| Dividend Return | 411.17% | 100% | F | 98% | N/A | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 1,347.58% | 13% | F | 2% | F | ||
| Risk Adjusted Return | 30.51% | 63% | D | 80% | B- | ||
| Market Capitalization | 0.01B | 33% | F | 63% | D | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
The stock is trading high compared to its peers median on a price to book value basis.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
The company had negative total cash flow in the most recent four quarters.
The company had negative total free cash flow in the most recent four quarters.
This stock has shown below median earnings growth in the previous 5 years compared to its sector
